These findings show that SIRT5 may be a tumor suppressorin this type of cancer and that its pharmacological activation (seecompound 14, section 4.1) impairsGOT1 activity and reduces PDAC cell viability.130 Hence, activating SIRT5 could be a promising strategy totarget PDAC. This evidence concerns the gene SIRT5 and neoplasm.